VIEWS: 40 PAGES: 8 POSTED ON: 1/28/2011
Lung Cancer Fall 2009 National Lung Cancer Partnership Hosts Symposium on Stigma of Lung Cancer documenting the stigmatization of lung cancer and the impact it has on patients. Dr. Ostroff theorized the stigmatization of lung cancer is a consequence of effective antismoking campaigns, and one way to lessen stigma is to increase understanding of nicotine addiction – to view smoking not as a character ﬂaw, but a biological or genetic predisposition to nicotine dependence. A better understanding of the pressures that lead people to start smoking could also help Dr. Wayne Steward, Dr. Jaimie Ostroff and Mary Ann Childers lead the roundtable discussion. reduce stigma surrounding lung cancer. Lung cancer is so tightly associated with Wayne Steward, PhD, (University of Drs. Steward and Ostroff both concluded smoking in the minds of the public, patients California - San Francisco) drew parallels that it is critical to develop support programs with lung cancer can feel stigmatized by between the causes and consequences of that help those affected by lung cancer their disease regardless of whether or not HIV/AIDS stigma and lung cancer stigma. manage the self-blame and shame that can they have ever smoked. Patients may feel Dr. Steward explained the degree of stigma accompany the disease. All lung cancer ashamed or unjustly blamed for their illness. associated with a disease depends on patients need to feel that they are not at fault Such feelings may increase psychological several variables: whether the patient is seen for having the disease. They still have the right and emotional distress, compromise as personally responsible for the condition; to quality health care and should be treated patients’ ability to develop social support whether effective treatments exist for the with respect. networks and even result in failure to seek condition; and whether the condition or side adequate medical care and psychological effects are readily apparent to others. In a roundtable discussion, speakers and support services. Dr. Steward also explained that widely meeting participants stressed the need to publicized advances in HIV treatment greatly unite lung cancer patients regardless of cause To address these issues head-on, the helped to combat the HIV/AIDS stigma. of their illness, to empower them with a voice National Lung Cancer Partnership sponsored He predicted that once well-publicized for advocacy and to combat the perception of De-stigmatizing Lung Cancer – Developing advances in lung cancer treatment occur, lung cancer as a self-inﬂicted death sentence. A Road Map for the Future: A Think-Tank the perception that lung cancer is an Presentation at the World Conference on untreatable, incurable disease will be Slides and Podcast Online Lung Cancer. The goal of this interactive countered, thus reducing stigma. A podcast of this symposium as well as forum, moderated by Mary Ann Childers (Res Public Group), was to discuss the issues Jamie Ostroff, PhD, (Memorial Sloan- Dr. Steward’s and Dr. Ostroff’s slides are contributing to lung cancer stigma and to Kettering Cancer Center) reviewed the available at identify strategies to dispel this stigma. growing body of scientiﬁc evidence NationalLungCancerPartnership.org . November is Lung Cancer Awareness Month: Inside: Support Research, Awareness & Change When you think about lung cancer, are you families and health care providers to access Letter from our President: angry about how few options there are for important information. Joan H. Schiller, MD screening and treatment? Do you wonder why the general public doesn’t seem to care Fifteen $10 gifts allow us to fund one day of Advancing Lung Cancer Research: enough about this horrible disease? critical lung cancer research. National Lung Cancer Partnership 2009 Annual Meeting Summary We’re working to change these perceptions, Your gift – in any amount – will directly help but we need your help! November is Lung lung cancer patients and their families. Stories of Strength: Cancer Awareness Month – the perfect time Survivor, Melissa Peterson to show your support. In this challenging We can’t do it without you. And we must Physician, Anil Potti, MD economy, we are not asking much – only do it today. Lung cancer patients and their $10. What can your gift do? families can’t wait. Patient Point of Interest: Update from ASCO and World Conference on One $10 gift allows us to mail educational Please donate today – visit Lung Cancer materials to ﬁve patients. NationalLungCancerPartnership.org, or mail your tax-deductible donation in the pre- Upcoming and Past Events Five $10 gifts keep our website running for addressed envelope enclosed. a month, enabling 30,000 patients, their Research, Awareness and Change Thank you for your support! 222 N. Midvale Blvd. Suite 6 Madison, WI 53705 P. 608.233.7905 F. 608.233.7893 www.NationalLungCancerPartnership.org Letter from the President Health care patients have access to the treatments they Board of Directors: reform. It’s in need, regardless of who is providing their President the news, the health insurance. Joan H. Schiller, MD topic of town hall University of Texas-Southwestern meetings and a Sincerely, Medical Center major presidential address and the concern Vice President of Americans Kathy S. Albain, MD everywhere. Cardinal Bernardin Cancer Center Health care Loyola University Chicago reform is also of Joan Schiller Joan H. Schiller, MD great concern Chief, Division of Hematology and Oncology Secretary/Treasurer to those in Deputy Director, Simmons Comprehensive Antoinette J. Wozniak, MD the cancer community because of the Cancer Center Karmanos Cancer Institute uncertainty about how it will affect cancer Andrea L. Simmons Distinguished Chair in Wayne State University care delivery. Cancer Research Richard N. Barg, JD, MBA Examples of people’s insurance coverage University of California, San Francisco working for them during a cancer diagnosis New Scientiﬁc Executive Committee and treatment are just as common as Members examples of problems. One young lung Amy Cipau, MBA cancer patient shared how her employer The Partnership’s Scientiﬁc Executive North Carolina Lung Cancer Partnership had a sick leave bank, so other employees Committee engages a group of premier Key Healthcare Partners were able to donate their unused sick doctors and researchers to develop a time to her. She never lost a paycheck or common agenda for research progress in Sarita Dubey, MD health insurance coverage during the nine lung cancer. We are grateful to these world- University of California, San Francisco months she had to be out of work to receive renowned individuals for giving their time to treatment for her cancer. A different patient help ensure the Partnership’s programs are of the highest quality, are based in scientiﬁc Deborah A. Fuderer couldn’t join a clinical trial because her insurance company deemed the treatment evidence, and are of the greatest beneﬁt to the lung cancer patients of today, tomorrow Jennifer Garst, MD “experimental,” even though the insurance Duke University Medical Center company would have only paid for the and beyond. standard treatment portion of the trial. Her The Partnership is pleased to welcome ﬁve physician called the insurance company’s Nancy Gatschet new members to our Scientiﬁc Executive Pennsylvania Lung Cancer Partnership denial ironic because if she had participated Committee: in the trial, she would have received her regular treatment, a very expensive drug, for Pasi Jänne, MD, PhD Andrea Bezjak, MDCM, MSc free. University of Toronto and Princess Margaret Dana-Farber Cancer Institute, Hospital Harvard Medical School One of the most challenging issues in Dr. Bezjak’s interests are in radiotherapy and the health care reform debate is the cost applications of new technologies in radiation Lorraine C. Pastore, MBA of imaging and cancer therapies. These planning for thoracic tumors. Reagent USA costs could deter doctors from ordering tests that could detect or rule out a cancer Yolonda Colson, MD, PhD Kelly Young, RN, MSN, ANP-C, AOCN diagnosis in people who may not ﬁt the Brigham and Women’s Hospital, Harvard Duke University Medical Center proﬁle of someone at risk. Such costs Medical School could also prevent a doctor from prescribing Dr. Colson’s research interests include a potentially beneﬁcial drug if he or she developing new technologies for delivering Staff: believes the patient may not be able to pay chemotherapy drugs directly to tumors. Regina Vidaver, PhD for it. It is important that scientiﬁc evidence, Executive Director not cost, be used to determine health care James Jett, MD needs and treatment. Mayo Clinic Kenda Schwarz Dr. Jett is an expert in clinical trials for the Director of Development & Outreach Many of the newest therapies are so early detection of lung cancer and treatment expensive because of the small number of of advanced lung cancer and mesothelioma. Alice Yuroff, PhD people using the treatments, the high cost of He is also the Editor-in-Chief of the Journal of Programs Manager developing the drugs and the lack of generic Thoracic Oncology. alternatives. These costs are difﬁcult for our Jackie Ford health care system to bear. However, these Anil Potti, MD Duke University Development Manager drugs have the potential to dramatically improve some lung cancer patients’ lives. It Dr. Potti’s research investigates genomic would be very difﬁcult to accept a system testing strategies to improve the treatment of Tracy Fischer, MSc people with lung cancer. Communications Manager in which patients don’t have access to beneﬁcial drugs because of cost. Fears of Ann Schwartz, PhD, MPH such a system have added to the debates Julie Chrisler Karmanos Cancer Institute, Wayne State surrounding health care reform. University Ofﬁce Manager Dr. Schwartz studies the genetics underlying There are several versions of health care lung cancer risk, including how risks differ Kim Bautz reform legislation making their way through between men and women and people from Development Administrative Assistant Congress, and we don’t know which one will different racial backgrounds. come out “on top.” What is clear, though, is Graphic Design & Layout: that we need to stay informed, as consumers Heather Hagerty and as advocates, to ensure that lung cancer National Lung Cancer Partnership - Fall 2009 > Page 2 Advancing Lung Cancer Research National Lung Cancer Partnership 2009 Annual Meeting Dr. Sequist is also planning studies to test aprepitant (Emend®) is combined with other whether the microﬂuidic chips can be used for standard anti-vomiting drugs, 75-85% of lung cancer screening and early detection. patients receiving chemotherapy experience complete control of vomiting. These three- Targeting for a cure: radiation therapy for drug treatments appear especially effective for lung cancer women. Walter Curran, MD, (Emory University) In another encouraging study, women were reviewed technological advances that deliver treated with a different three-drug combination higher doses of radiation targeted at a tumor (dexamthasone, aprepitant and palonosetron to minimize damage to surrounding healthy [Aloxi®], a newer serotonin receptor inhibitor). National Lung Cancer Partnership research grant tissue. Ninety-ﬁve percent of patients receiving this recipients Dr. Michele Coté, left, and Dr. Richard combination experienced no vomiting at Pietras, right, and Partnership President, Dr. Joan Schiller, center, presented at the meeting. The challenge now is to pinpoint where the all and 66% experienced no nausea during tumor is. Lung cancer tumors move, not only their chemotherapy treatment. Although this with breathing, but also with circulation and was a small study and needs to be repeated The Partnership held its 7th Annual Meeting, heartbeats. Thus, advances in tumor imaging Advancing Individualized Care in Lung with more patients, it provides hope that are critical to improvements in how patients chemotherapy-induced nausea and vomiting Cancer: New Hope for Screening and receive radiation therapy. Treatment, on May 29 in Orlando, FL. This can be completely controlled for many patients. symposium brought together researchers, Recent advances in imaging are improving health care professionals and patient Targeting critical molecular pathways in lung how patients receive radiation therapy. Fusion cancer to ﬁnd more effective treatment advocates to learn about the progress towards technology allows images from different personalizing care for lung cancer patients. imaging equipment to be combined. Dynamic David Beer, PhD, (University of Michigan) imaging allows monitoring of the tumor described his work applying sophisticated Detecting circulating tumor cells: movement throughout the entire respiratory implications for screening, diagnosis and genetic analyses to identify what genes and cycle. Online imaging allows a patient’s tumor processes are most critical in lung cancer. treatment to be imaged in the room where they will Studies like this may determine which tumors receive therapy and guide radiation treatment will be aggressive and better predict which All cancers, potentially even in their earliest in real time. Clinical trials have led to these stages, shed cells into the circulatory patients will respond to certain therapies. improvements in the quality of radiation system. A portion of these cells may play therapy and, thus, better patient outcomes. a role in forming metastases. An in-depth Tony Mok, MD, (Chinese University of Hong understanding of these circulating tumor Kong) discussed results of the ground-breaking Control of chemotherapy-induced nausea IPASS clinical trial, which demonstrated a cells (CTCs) may allow for earlier detection of and vomiting: new studies and new agents invasive disease, increase our understanding signiﬁcant response to the targeted therapy of metastasis and allow monitoring of disease drug geﬁtinib (Iressa®) in lung cancer patients Chemotherapy-induced nausea and vomiting with tumors containing mutations in the progression or response to treatment simply can seriously impact quality of life for patients by using blood samples. However, CTCs epidermal growth factor receptor (EGFR) and may even prevent patients from receiving gene. Dr. Mok discussed how these ﬁndings constitute less than one cell in a billion in the or completing the most effective cancer blood, making detecting and studying these and others will help doctors select and treat treatments. Women, and especially younger patients based on molecular biomarkers in cells technically challenging. women, are at greater risk of experiencing addition to clinical parameters. nausea and vomiting during their cancer Lecia Sequist, MD, (Harvard Medical School) treatments than men. Understanding ways to reviewed the latest developments in the use of Heather Wakelee, MD, (Stanford University) control nausea and vomiting during treatment reviewed the role of vascular endothelial CTCs for screening, diagnosis and treatment of is critical to providing the best possible care for lung cancer. She described her team’s work in growth factor (VEGF) pathway inhibitors in patients. the treatment of lung cancer. She discussed adapting microﬂuidic chips, a new technology that captures CTCs so they can be studied. how these drugs may affect men and women Richard Gralla, MD, (North Shore-Long Island differently and the potential role estrogen may The small chips contain 78,000 microscopic Jewish Health System) reviewed the newest posts covered in antibodies that can “grab” play in treatment. anti-nausea and anti-vomiting agents and the CTCs. discussed ways men and women differ in their National Lung Cancer Partnership research response to these drugs. grant recipients, Michele Coté, PhD, (Wayne Although this technology is still in early development, it is showing promise for State University) and Richard Pietras, MD, Thirty years ago, nearly all patients PhD, (UCLA) described their work investigating practical applications. In one study, Dr. Sequist experienced chemotherapy-induced nausea and colleagues counted the number of CTCs estrogen pathway molecules as markers of and vomiting. By the late 1990s, treatment lung cancer survival and as potential targets for in patients’ blood during treatment. In several with two-drug combinations – dexamthasone patients, the numbers of CTCs detected therapy. plus serotonin receptor inhibitors, such as correlated well with their tumor burden, ondansetron (Zofran®) – controlled vomiting suggesting it might be possible to monitor Details of these latter presentations will be in 50-60% of patients. This therapy is still reviewed in an upcoming article in the Journal response to treatment using this one-step considered standard of care for many patients blood test. of Thoracic Oncology. We will announce treated with certain types of chemotherapy. the publication of this article as soon as it is However, this treatment tends to be less available. Dr. Sequist and her colleagues also effective for women. demonstrated it is possible to detect and characterize epidermal growth factor receptor Dr. Gralla presented new research showing Save the Date! (EGFR) mutations in CTCs from lung cancer that adding a third type of drug to the patients. In the future, this technology could The Partnership’s next Annual Meeting will treatment regimen can result in substantial be June 4, 2010, in Chicago, IL. allow doctors to genetically proﬁle tumors alleviation of symptoms. These new drugs using a blood test, potentially removing the block NK1 receptors in the vomiting center need for biopsies. of the brain. When an NK1-inhibitor such as National Lung Cancer Partnership - Fall 2009 > Page 3 Stories of Strength A Survivor’s Story After a biopsy, I was diagnosed with Stage IV on maintaining excellent health, traveling adenocarcinoma of the lung. It was the last and spending time with my family and Melissa Peterson was thing I expected, as I thought (then) that only friends. Professionally, I am splitting my time diagnosed with lung smokers got lung cancer. And except for a bit between my communications job and doing cancer in June 2008. of a fondness for red wine and chocolate, I advocacy work on behalf of the Partnership With a young daughter have always been a very healthy, outdoorsy, and for the Global Resource for Advancing and a feisty spirit, she active person. Cancer Education. Melissa Peterson with her is ﬁghting the disease daughter, Lucie with everything she’s Q: How did you handle the news? Q: What do you want other patients to got. A: It was the most terrifying and gut- know? wrenching news imaginable. My ﬁrst A: I believe we are now entering a phase of Q: What were the circumstances around thoughts went to my daughter, Lucie. My hope, where targeted therapies seem to be your diagnosis? mother died of a brain tumor when I was two gaining ground in the battle. That’s deﬁnitely A: I was diagnosed after returning home years old, and being a mother to my ﬁve-year- something to hang on to if you’re unlucky from a 40th birthday trip to Italy with my old daughter has been one of the greatest enough to get this disease – even ﬁve years family. During the trip, I was having some odd joys of my life. ago, we didn’t have as many options for sensations in my left arm, and noticed some therapy. I’m past my one-year mark, and so hard lumps around my collarbone…along with Being told that I had an incurable cancer far, my once-a-month maintenance therapy some disconcerting amounts of perspiration that would, in all likelihood, shorten my time seems to be holding the beast at bay. This under that armpit. I also had a chronically with her, devastated me. But it also made makes me feel incredibly fortunate and also sore hip, which I had chalked up to my over- me resolve to ﬁght as hard as I could – not humbled, as I know that everyone’s struggle enthusiastic, pre-40th birthday workouts! only to live longer for her, but also to make a with this disease is different. difference for others given this diagnosis. When we got back to Seattle, I went to my Want to know more about Melissa’s doctor, who seemed pretty concerned – I Q: How has your life changed? experience with lung cancer? went in for scans which showed only a tiny A: After going through treatment – consisting spot on my lung, but also a ton of lymph node of whole brain radiation and chemotherapy, Visit our website at which went surprisingly well, given their NationalLungCancerPartnership.org to follow involvement, bone involvement and brain our bloggers, Melissa and Lisa Woody, MD, metastases. nature – I have become much more focused as they share their stories of strength, OR to on what I want to do, both personally and share your own story! professionally. Personally, I want to work A Physician’s by clinicians and researchers alike. Some of my mind, serves that very important purpose, Perspective the people who have helped me the most in bringing people together, to deﬁne the have been senior lung cancer investigators future of lung cancer research and therapy. Anil Potti, MD, is a doctor and at different institutions - there is a sense researcher at Duke University of mentoring that goes far and beyond Q: What is your greatest challenge as a Medical Center where he institutional alliances and collaborative physician, researcher and Partnership investigates genomic testing efforts. This is very unique to the lung cancer Committee member? strategies to improve the ﬁeld. A: I have a lovely family, and balancing my treatment of people with academic life with the needs of my family is Anil Potti, MD lung cancer. Dr. Potti is also Q: What would you like patients to know always a challenge for me. I never miss an a valued member of the about lung cancer treatment now and for opportunity to thank my beautiful wife and National Lung Cancer Partnership’s Scientiﬁc the future? three wonderful girls, so I will do that here Executive Committee. A: These are exciting times. We are on the again – they keep me going when the going cusp of a major turnaround in our approach gets tough. But, the fact is, the challenges I Q: What inspired you to enter lung cancer to treating lung cancer. The development of a face are nothing compared to what cancer research and treatment? whole new repertoire of drugs will lend itself patients go through. A: Cancer biology always fascinated me. I just to more effective strategies, moving beyond gravitated to a disease about which very little traditional chemotherapy. Several recent Q: As a member of the Partnership’s was known, but one where you could make a discoveries and strategies will pave the way Scientiﬁc Executive Committee, what do tremendous difference in people’s lives, even for more personalized therapy that will likely you see as the greatest strength of the with small advances. improve response rates and survival. organization? A: The ability to motivate and lead, in all Q: What advances in lung cancer research “For too long, the lung cancer respects. For too long, the lung cancer community has waited for an organization have made you most hopeful? community has waited for an to lead and bring all the forces together in A: We now understand the biologic organization to lead and bring all the underpinnings of lung cancer better than ever this war against a deadly disease. What the before. This will lead the way in designing forces together in this war against a Partnership has achieved in just a few years rational clinical trials of new therapies that will deadly disease. What the Partnership speaks for itself. likely have a major impact in outcomes. One has achieved in just a few years Q: What is the most important thing you example is the importance of EGFR mutation speaks for itself.” testing and most recently the promise of have learned from your patients? targeting mutations involving the ALK gene. A: A patient once told me that, “Hope beats Q: What role do you see the Partnership despair every day of the week and twice on playing in the future of oncology? Sunday.” A day does not go by where I don’t Q: What would you like young professionals A: My dad used to say that there are three entering the ﬁeld to know? remind myself of that. As most health care types of people in this world – Leaders, professionals would agree, we learn more A: There is both tremendous promise and Followers and Builders. While most fall into opportunity for a motivated investigator in the from our patients than from anyone else. the top two categories at various points in ﬁeld of lung cancer. Personally, as a junior our lives, the ones that are critical to eventual investigator, I have been embraced and success and bring the leaders and followers welcomed into the lung cancer community together are the builders. The Partnership, in National Lung Cancer Partnership - Fall 2009 > Page 4 Patient Point of Interest Update from ASCO and World Conference on Lung Cancer Two important disease will have at EGFR were also described. For example, conferences were their cancer recur. If preliminary data using the drug BIBW2992 held this summer: doctors could better in patients with tumors with EGFR mutations the American Society understand who showed the drug controlled the disease in the of Clinical Oncology is likely to have a majority of patients. This and other agents in (ASCO) Annual recurrence, those testing give great hope that we will soon be able Meeting and the 13th patients could be to control disease caused by tumors with EGFR World Conference on followed closely and mutations. Lung Cancer (WCLC). offered additional Both conferences therapy after Personalizing therapies highlighted lung cancer surgery. Scientists With increased understanding of the genetic research advances are seeking to understand who is and who is ﬂaws that drive certain cancers comes the that may signiﬁcantly not likely to experience a recurrence, using a ability to better predict which patients will beneﬁt improve lung cancer patients’ survival. simultaneous analysis of 100 genes. If this from particular therapies. Data presented multi-gene analysis presented at ASCO can be at ASCO suggest that individuals with early- Understanding lung cancer risk successfully used in the clinic, doctors may be stage tumors that express low levels of two Recent studies show estrogen can affect lung able to identify which early-stage lung cancer speciﬁc proteins are more likely to beneﬁt from cancer growth and progression, just as it does patients will beneﬁt from more aggressive chemotherapy given after surgical removal for breast and ovarian cancers. Results from therapy. of their tumor. These two proteins, called the Women’s Health Initiative (WHI) presented mutS homolog 2 (MSH2) and excision repair at ASCO further suggest that, for women Maintenance therapies cross-complementation group 1 (ERCC1), are with lung cancer, continued use of hormone After an initial chemotherapy treatment involved in repairing damage caused by platin- replacement therapy (HRT) may worsen their regimen, patients with non-squamous lung based chemotherapies. As additional genetic chance of survival from the disease. HRT cancer who were given pemetrexed (Alimta®) testing methods are developed and matched to did not, however, increase a person’s risk of until the disease showed signs of progressing available therapies, patients can expect more developing lung cancer. These results add to lived signiﬁcantly longer than those who ended personalized treatments, hopefully resulting in the body of evidence suggesting that women their treatment after the initial chemotherapy. improved survival and cure rates. going through menopause should use the This ﬁnding, presented at ASCO, has led lowest dose of HRT for the shortest period of to a new FDA approval of pemetrexed for Quality of life improvements time to control their menopausal symptoms. maintenance therapy in lung cancer. When a new drug, vandetanib (Zactima®), was For women who have been diagnosed with added to standard chemotherapy for advanced- lung cancer, results of this study suggest HRT A similar trial treating advanced-stage lung stage patients, patients experienced improved should be discontinued. cancer patients with erlotinib (Tarceva®) after progression-free survival, as well as a better initial chemotherapy also suggests this agent quality of life during the course of the treatment. Prevention can provide a beneﬁt in progression-free However, in spite of these positive effects of the Individuals who smoked in the past remain survival, as well as improving overall survival. drug, patients didn’t live longer when vandetanib at risk for lung cancer for up to 20 years after Another study showed the combination of was added to their therapy regimen. More they quit smoking. In order to decrease the bevacizumab (Avastin®) and erlotinib given after studies are underway to better characterize who risk of developing the disease, research in initial chemotherapy provided a substantial is most likely to beneﬁt from vandetanib. “chemoprevention” – using drugs to prevent improvement in progression-free survival versus disease – is underway. One study discussed treatment with bevacizumab alone. Conclusion at WCLC showed the drug iloprost (Ventavis®) These brief summaries represent only a effectively reversed airway damage in people Progression-Free Survival Rate describes the fraction of the advances that are being made who used to smoke. This airway damage may percentage of people who do not experience in understanding how we can better prevent, lead to the development of lung cancer. If any new tumor growth or cancer spread during screen for, diagnose and treat lung cancer. these results are seen in larger numbers of or after treatment, including those whose Future lung cancer research offers great people, iloprost and agents like it could be disease has either completely or partially promise towards ending lung cancer’s reign as prescribed to people after they quit smoking to responded to treatment, or those whose the #1 cancer-killer. help prevent lung cancer. disease is stable (the cancer is still present but not advancing). Lung Cancer Call to Action Screening updates What if doctors could detect lung cancer Experts caution, however, that both pemetrexed The National Lung Cancer Partnership is just by “smelling” a person’s breath? At the and erlotinib are already known to be effective pleased to announce a partnership with WCLC, researchers described their progress in for second-line treatment (once the disease differentiating lung cancer from other cancers EmergingMed, a personalized clinical trials and normal cells by using new technologies to has progressed after the ﬁrst line of treatment), matching service. identify the chemicals being given off by the so it is not clear whether the timing of the cells – essentially “smelling” them. Although medication is what’s important, as opposed to just getting it at all. Nonetheless, these This unique service helps patients quickly early results are promising, further studies results make clear that patients and their identify clinical trials that match their speciﬁc need to be completed before such an advance doctors should discuss the pros and cons of diagnosis and treatment history. Patients could be used in the clinic. maintenance therapy before the ﬁrst line of are encouraged to call EmergingMed as soon Another new screening technology, 3D Cell treatment is complete. as they are diagnosed, in order to maximize Analysis, was also presented at WCLC. This Targeted therapies the potential beneﬁts of the service. method uses computed tomography (CT) to Much interest at both conferences centered on look for irregular cells, which are indicative of agents designed to inhibit the epidermal growth For more information, please visit cancer, in the sputum people cough up. This factor receptor (EGFR). Mutations in EGFR technology could prove useful in determining emergingmed.com/networks/ whether someone has pre-cancerous or have been found to drive the growth of some NationalLungCancerPartnership/ . cancerous cells in their lungs at a very early tumors. Results from the IPASS (Iressa Pan- stage. Asian Study) trial, described in the summary of the Partnership’s Annual Meeting (see page Predictors of disease severity & progression 3), were cited throughout both conferences as Lung cancer in its earliest stage is typically demonstrating the utility of targeted therapy to treated with surgery. However, approximately substantially improve progression-free survival 30% of people with the earliest stage of rates in those with activating EGFR mutations. Advances in testing other agents directed National Lung Cancer Partnership - Fall 2009 > Page 5 Upcoming Events Free to Breathe® Events 2010 Free to Breathe® Events 2009 Fall/Winter Events Planning has already begun for the 2010 Free to Breathe® season! Run/Walk East Watch FreetoBreathe.org for Providence, RI – October 17 announcements of locations near you. TM Philadelphia, PA – November 1 Save the Date! South Lake Charles, LA – March 27 Punta Gorda, FL - October 31 Boone, NC – October 31 Raleigh, NC – November 7 Look Deeper Concert Athens, GA – November 7 Join us for the ﬁrst Look Deeper Concert on Jacksonville, FL – November 7 November 13, 2009 in Dallas, TX! Columbia, SC - November 21 Triad, NC – November 14 To purchase tickets, please visit The Free to Breathe® event series unites NationalLungCancerPartnership.org/ people who are passionate about raising Midwest LookDeeperConcert09 . public awareness and vital funding to ﬁght Dayton, OH - November 7 lung cancer. West Thank You! During 2009, Free to Breathe® has grown Seattle, WA – November 8 We would like to thank all of our local event to 23 events around the country! organizers, advocates and volunteers who Information about each event location, Nationwide National Walk – November 7 give their time and effort to make these how to register, form a team, donate, events successful. Without your dedication, volunteer or sponsor an event is available our research, education and awareness at FreetoBreathe.org . Marathon programs would not exist. Raleigh, NC – November 1 We appreciate and applaud your efforts! November is Lung Cancer Yogathon Awareness Month Baltimore, MD - November 1 To have quantities of this newsletter or our other Durham, NC – December 21 educational materials delivered to your ofﬁce or Show your support for lung cancer clinic for FREE, please email us at research, awareness and change info@NationalLungCancerPartnership.org . by joining thousands of lung cancer survivors, family, friends and advocates across the country and participating in a Free to Breathe® event near you! Past Events The 2009 Free to Breathe® season has Pennsylvania Chapter Update campaign designed by students at the already included these events: It has been a busy summer for the Art Institute of Philadelphia under the Pennsylvania Chapter, with the ofﬁcial leadership of Professor Linda Karp, Lake Charles, LA – March 14, 2009 Chapter launch and several fundraising Chapter Secretary. Los Angeles, CA – August 2, 2009 events! Toldeo, OH – August 29, 2009 In September, the Pennsylvania Lung Tacoma, WA – September 19, 2009 The Life & Breath Party in Plattsburgh, Cancer Partnership’s Board of Directors Glastonbury, CT - September 20, 2009 NY, hosted by Brian Brubaker, not only held the ﬁrst strategic planning meeting to Kansas City, MO – September 27, 2009 raised funds but also spread awareness shape the chapter’s direction for the next Madison, WI – September 27, 2009 with a full-page article in the local press. 3 years. And, of course, the chapter is Lincoln, NE –October 3, 2009 preparing for the largest Free to Breathe® Lanes for Lungs in Philadelphia was event in the country in Philadelphia on hosted by Nicholas Tees and his family November 1. on the ﬁrst anniversary of his father’s death. Nicholas’ dad loved to bowl, so the bowling alley was overﬂowing with people celebrating his life and raising much- needed funding. Be the Light celebrated the founding of the Chapter. Guest speakers included Dr. Mike of Fox News and Dr. James Stevenson, of the Abramson Cancer Center at the University of Pennsylvania. The event included an exhibit of “Faces Participants run in the Kansas City of Lung Cancer” from the Mofﬁt Cancer Pennsylvania Lung Cancer Partnership Board Secretary Free to Breathe® 5K Run/Walk. Linda Karp, Board President Nancy Gatschet, Robin Center in Florida, and the debut of the Barg and Bill Mignucci attend the Pennsylvania Philadelphia Free to Breathe® PSA Chapter Launch event, Be The Light. National Lung Cancer Partnership - Fall 2009 > Page 6 Research, Awareness and Change Second Lung Cancer Advocacy Summit a Rewarding Experience The Advocacy Summit brought together a increasing public awareness and research diverse group of 68 advocates, including funding. These efforts will help to bring 24 lung cancer survivors. The group also about the change that is needed for future included caregivers, family members, friends lung cancer patients and their families. and medical professionals. One of the highlights was a tour of the University of Texas-Southwestern Medical Center laboratory facilities. Summit participants learned about several cutting- edge advances in lung cancer research directly from researchers and gained important insights into the research process. The National Lung Cancer Partnership sponsored the second annual Lung Cancer Advocacy Summit participants put what they Advocacy Summit from April 23-26, 2009, in learned into action during the conference by organizing a poignant candlelight vigil in Advocates learn ﬁrst-hand about lung cancer research Dallas, TX. at the University of Texas-Southwestern honor and memory of those affected by lung Medical Center labs. This conference included presentations, cancer. discussions and interactive brainstorming on advocacy topics such as: engaging the Advocacy Summit participants clearly media, crafting a message, legislative identiﬁed that their two major concerns are Save the Date! advocacy and raising community awareness. insufﬁcient funding of lung cancer research and the need to get high-quality information The 2010 Lung Cancer Advocacy Summit will The goal of the Advocacy Summit is to be held April 22-25 in Tampa, Florida! empower advocates by giving them the tools, to patients as quickly as possible after diagnosis. Participants also expressed Look for details in early 2010 at knowledge and courage to become conﬁdent and effective advocates for lung cancer their desire for the lung cancer community NationalLungCancerPartnership.org . research and awareness. to come together with a common goal of In the News SELF Magazine mentioned the Partnership Ted Casablanca wrote an article about few patients are currently participating in the as part of an article about lung cancer Kathryn Joosten’s recurrence of lung cancer clinical research process. survivor and advocate Montessa Lee in the in his E! Online blog, The Awful Truth on October issue. September 14. The article directed readers The Wall Street Journal published a to the Partnership’s website for information letter to the editor by Regina Vidaver, PhD, Good Morning America featured the about getting involved in the ﬁght against Parternship Executive Director, in the May Partnership’s broadcast public service lung cancer. 30 issue. The letter was in response to an announcement (PSA) as part of a segment article about comparing the effectiveness of about controversial PSAs on September 23. The American Thoracic Society Public medical interventions. Advisory Roundtable’s September-October CNN ran a similar story on the morning news E-Newsletter included an article about how The Chicago Sun-Times featured Kathy that also featured a clip of the Partnership’s the Partnership’s PSA is raising lung cancer Albain, MD, Partnership Board Vice President, broadcast PSA on September 24. awareness. explaining how lung cancer affects men and women differently in the May 19 article, “No The Los Angeles Times ran an article The New York Times published a letter to Butts About It”. about controversial cancer public service the editor by Joan Schiller, MD, Partnership announcements on September 22 using the President, in the August 6 issue. The letter Partnership’s PSA campaign as an example. was in response to an article about why so Memorial Giving: Donations have been made to the National Lung Cancer Partnership in memory of the following people (April 17 through September 17, 2009): Lucy Acevedo EJ Cole Shelly Goldstein Thomas McDonough Susie Smith Bucky Alexander Theresa Rose Convertino Barbara Goodman Jill McKay Marcos S. Sodre Innocenzo Ambrosetti John S. Cordero Jr. Johnny S. Greer Joan McVay Dorothy Warm Stettner Zwie Amitai Lynn Corts William C. Grifﬁn, MD Linda Mills Jim Stevens Karen Antonucci Jill Cotoia Ruth Grimsley Gladys Morrissey David Stockwell David Atkins Patricia Jean (Trish) Creegan Bill Hamberg Kay Murphy Edward Sweeney Harry Baseman Mary Pat Darling Anna A. Hamel Nancy Venos Neilson Daniel T. Sweeney Jr. Rose Baseman Doris Dillon Elinor Hanna Karen Parles Max Taft Paula Belott Patrick Duberg Delbert Hardratch Robert L. Pensinger George Turen Allen Berman Patrick Duffy Tim Harvell Charles Raynard Joyce Turosky Abuelo Bernal Jonnie Duncan Bruce Hayworth Mr. Reed James M. Vine Lorraine Blackwell Kim Andrews Ebert Ella Marie Jones Margo A. Reynolds Gary Ward Nancy Boals Mary Ellis Lynne Jones Roberto Rios Janice Weir Tommy Boardman Joan Fazzolari Madge (Judy) Joplin Michaelene (Mickey) Robida Lee M. Williams John Bowden Estelle Flanagan John Kelley Robert Rothlein David Woody Sheryl Brody Madeline Fox Mildred Kial Betty Sapolsky Louis Wright Carolyn Burchﬁeld Ruth Frerichs Janet Kohen Evelyn Schramm Harriet Butcher Michael Gaudreau Red Lee Jeffrey Scott Leo Cabro Shirley Jane Geisinger Gracie Levasseur Karen Siegmund Bernardina Leynes Casana Denise Gess William Lynch Stephen Simmonett Jean E. Chipman Matthew B. Ginnetty Joyce Lyons Dr. Susan L. Sipes Psan Chon Kara S. Gobron Patricia Alice Maenza Carlene Smail National Lung Cancer Partnership - Fall 2009 > Page 7 Learn about the latest advances in lung cancer screening, diagnosis and treatment! See inside for information about upcoming Free to Breathe® events and other ways that you can get involved in the ﬁght against lung cancer. National Lung Cancer Partnership is dedicated to decreasing deaths due to lung cancer, and helping patients live longer and better, through research, awareness and advocacy. Thanks to Genentech BioOncology, Novartis Pharmaceuticals, Abraxis BioScience and Boehringer Ingelheim Pharmaceuticals, Inc., for unrestricted educational grants that made this issue of the Lung Cancer Voice possible. PERMIT NO 601 BEDFORD PARK IL PAID U.S. POSTAGE PRSRT STD
"Lung Cancer ung Cancer"